December 19, 2011
EFPIA Japan

Philippe Fauchet becomes new chairman of EFPIA Japan

EFPIA Japan appoints Philippe Fauchet (President & Representative Director,GlaxoSmithKline KK) as a new chairman from January 1st, 2012.
Masuhiro Kato (AstraZeneca) becomes a new vice chairman and Hiroyuki Mitani(Novartis Pharma) stays in the current position of vice chairman. Both vice chairmen andfour directors will support Philippe Fauchet, new chairman of EFPIA Japan. On the sameoccasion, Director
General changes from Takahiro Maehama (AstraZeneca) to Keiko Nakamura(GlaxoSmithKline).
Philippe Fauchet reiterates vision of EFPIA Japan as follows;“Society and healthcare environment are changing dramatically. In this era of reform,EFPIA Japan consisting of research-driven pharmaceutical companies based in EU
will continue proposing dialogue and solutions to the many issues faced by thepharmaceutical industry such as sustaining the new pricing system supporting
innovation, expediting the access of Japanese patients to global innovation andreducing the drug lag, pursuing better balance between prevention and treatment forimprovement of the public health. We would like to further contribute to improve
Japanese healthcare and always bear the concept of ‘patient first’ in mind”

Contact
Hideto Kita, Chairman of PR committee〒106-8618 4-17-30, Minato-ku, Nishiazabu, Tokyo
Novartis Pharma KK
TEL：03-3797-8009
Mail：hideto.kita@novartis.com__________________________________________________________________
c/o AstraZeneca K.K.
Marunouchi Trust Tower Main Building, 1-8-3 Marunouchi, Chiyoda-ku, Tokyo 100-0005
Tel: +81-3-6301-3066 Fax: +81-3-6268-2861

Philippe Fauchet ProfileDate of Birth： 2 November 1957
Current position：GlaxoSmithKline K.K , President, Representative Director
 Business Career
Since Jan 2010
GLAXOSMITHKLINEJan 2010GlaxoSmithKline K.K Tokyo, Japan
President, Representative Director
1996-2009
SANOFI-SYNTHELABO / SANOFI-AVENTIS
2008– 2009 sanofi-aventis Group Paris, France
Senior Vice President, Head Corporate Business Development
Member of sanofi-aventis Management Committee
2005 – 2008 sanofi-aventis Japan Tokyo, Japan
President & Representative Director
Member of sanofi-aventis Management Committee
2001- 2004 SANOFI-SYNTHELABO K.K. Tokyo, Japan
President & Representative Director
1996 -2001 Various Regional Positions (Asia, Eastern Europe)
1984 – 1996 ROUSSEL UCLAF / HOECHST Group
Various positions including Japan and Korea
 Academic Background1980
Law degree at Paris X - University
1979
M.B.A. at ‘Ecole des Hautes Etudes Commerciales’ (H.E.C.)
Paris, France☆EFPIA Japan Board members as of January 1st, 2012
Chairman ：Philippe Fauchet (GlaxoSmithKline K.K.)
Vice Chairman ：Masuhiro Kato (AstraZeneca K.K.)
Vice Chairman ：Hiroyuki Mitani (Novartis Pharma K.K.)
Director ：Jez Moulding (sanofi-aventis K.K.）
Director ：Sebastian Guth (Bayer Yakuhin, Ltd.)
Director ：Claus Eilersen (Novo Nordisk Pharma Ltd.)
Director ：Mark Smith (Merck Serono Co., Ltd.)
Director General ：Keiko Nakamura (EFPIA Japan)

(New)
(New)

(New)

__________________________________________________________________
c/o AstraZeneca K.K.
Marunouchi Trust Tower Main Building, 1-8-3 Marunouchi, Chiyoda-ku, Tokyo 100-0005
Tel: +81-3-6301-3066 Fax: +81-3-6268-2861